Stevanato Group S.p.A.
General ticker "STVN" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $5.9B (TTM average)
Stevanato Group S.p.A. does not follow the US Stock Market performance with the rate: -6.5%.
Estimated limits based on current volatility of 1.9%: low 18.35$, high 19.07$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-06-05, amount 0.06$ (Y0.32%)
- Total employees count: 4652 as of 2021
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.20$, 26.89$]
- 2026-12-31 to 2027-12-31 estimated range: [17.43$, 28.46$]
Financial Metrics affecting the STVN estimates:
- Positive: with PPE of 34.4 at the end of fiscal year the price was neutral
- Positive: 7.54 < Operating profit margin, % of 16.07
- Positive: Interest expense per share per price, % of 0.46 <= 0.73
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 5.02
- Negative: Industry operating cash flow per share per price (median), % of 1.51 <= 5.46
- Negative: Investing cash flow per share per price, % of -5.48 <= -4.41
- Positive: -9.55 < Industry operating profit margin (median), % of -3.62
- Negative: 42.59 < Shareholder equity ratio, % of 58.43 <= 64.29
Short-term STVN quotes
Long-term STVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €1,085.35MM | €1,104.04MM | €1,139.48MM |
| Operating Expenses | €884.63MM | €942.89MM | €956.40MM |
| Operating Income | €200.72MM | €161.14MM | €183.08MM |
| Non-Operating Income | €-11.17MM | €-0.85MM | €-1.44MM |
| Interest Expense | €4.32MM | €6.86MM | €21.80MM |
| R&D Expense | €35.67MM | €31.67MM | €24.40MM |
| Income(Loss) | €189.55MM | €160.29MM | €181.64MM |
| Taxes | €43.86MM | €42.52MM | €47.35MM |
| Net Income(Loss)* | €145.63MM | €117.78MM | €134.28MM |
| Stockholders Equity | €1,132.53MM | €1,404.34MM | €1,485.87MM |
| Inventory | €255.32MM | €245.22MM | €268.09MM |
| Assets | €2,071.58MM | €2,328.82MM | €2,542.82MM |
| Operating Cash Flow | €105.21MM | €155.78MM | €274.79MM |
| Capital expenditure | €441.93MM | €313.57MM | €253.35MM |
| Investing Cash Flow | €-421.22MM | €-310.21MM | €-262.15MM |
| Financing Cash Flow | €158.03MM | €183.22MM | €21.19MM |
| Earnings Per Share** | €0.55 | €0.43 | €0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.